Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 40, Issue 3, 2015, Pages 285-293

  Undre, Nasrullah ^a   Pretorius, Benjamin ^b   Stevenson, Paul ^c  

^a ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

^c Astellas Pharma GmbH Munich ^*  (Germany)

Author keywords

Hepatic; Liver; Micafungin; Pharmacokinetics; Safety

Indexed keywords

ALBUMIN; MICAFUNGIN; ECHINOCANDIN; LIPOPEPTIDE;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING SITE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRURITUS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; CASE CONTROL STUDY; FEMALE; LIVER; LIVER DISEASES; MALE; METABOLISM; MIDDLE AGED;

AREA UNDER CURVE; CASE-CONTROL STUDIES; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; LIVER; LIVER DISEASES; MALE; MIDDLE AGED;

EID: 84940575440     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0204-y     Document Type: Article

References (26)

1. Astellas Pharma (2013) Mycamine: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000734/WC500031075.pdf. Accessed 19 March 2012
2. Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ (2010) Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 87(1):93-99. doi: 10.1038/clpt.2009.200
3. de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21(7):899-907. doi: 10.1111/j.1365-2036.2005.02427.x
4. Dowell JA, Stogniew M, Krause D, Damle B (2007) Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 47(4):461-470. doi: 10.1177/0091270006297227
5. Fromtling RA (2002) Micafungin sodium (FK-463). Drugs Today (Barc) 38(4):245-257
6. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, Bekersky I, Walsh TJ (2001) Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 45(12):3322-3327. doi: 10.1128/AAC.45.12.3322-3327.2001
7. Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I (2005a) Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45(9):1018-1024. doi: 10.1177/0091270005279274
8. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I (2005b) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45(10):1145-1152. doi: 10.1177/0091270005279580
9. Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I (2005c) Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45(8):954-960. doi: 10.1177/0091270005278601
10. Jarvis B, Figgitt DP, Scott LJ (2004) Micafungin. Drugs 64(9):969-982
11. Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A (2007) Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 51(2):787-790. doi: 10.1128/AAC.00673-06
12. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519-1527. doi: 10.1016/S0140-6736(07)60605-9
13. Lass-Flörl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3):197-205
14. Merck Sharp & Dohme Limited (2011) Cancidas (caspofungin) summary of product characteristics. Merck Sharp & Dohme Limited. http://www.medicines.org.uk/emc/medicine/12843#PHARMACOKINETIC-PROPS. Accessed 19 March 2012
15. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA (2006) Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44(2):324-326. doi: 10.1128/JCM.44.2.324-326.2006
16. Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S, Dilzer S, Lasseter KC, Stone JA (2007) Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 47(8):951-961. doi: 10.1177/0091270007303764
17. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45(7):883-893. doi: 10.1086/520980
18. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133-163. doi: 10.1128/CMR.00029-06
19. Pfizer Inc. (2010) Eraxis™ (anidulafungin) prescribing information. Pfizer Inc., http://labeling.pfizer.com/ShowLabeling.aspx?id=566. Accessed 19 March 2012
20. Undre N, Stevenson P, Baraldi E (2012a) Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis. Eur J Drug Metab Pharmacokinet 37(1):31-38. doi: 10.1007/s13318-011-0063-8
21. Undre N, Stevenson P, Kuse ER, demeyer I (2012b) Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidemia. Open J Med Microbiol 2(3):84-90. doi: 10.4236/ojmm.2012.23012
22. Undre NA, Stevenson P, Freire A, Arrieta A (2012c) Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 31(6):630-632. doi: 10.1097/INF.0b013e31824ab9b0
23. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407-1416. doi: 10.1086/422312
24. van der Elst KC, Brüggemann RJ, Rodgers MG, Alffenaar JW (2012) Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transpl Infect Dis 14(4):440-443. doi: 10.1111/j.1399-3062.2011.00716.x
25. Wiederhold NP, Lewis JS 2nd (2007) The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 8(8):1155-1166. doi: 10.1517/14656566.8.8.1155
26. Yamato Y, Kaneko H, Tanimoto K, Katashima M, Ishibashi K, Kawamura A, Terakawa M, Kagayama A (2002) Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother 50:68-73